MSD Korea said Lee Hee-seung, its external affairs lead, has been appointed as the Commercial Strategy & Operations Director for MSD Australia and New Zealand (MSD ANZ).
Lee, who will start her role on Feb.1, plans to play a pivotal role in formulating and executing commercial strategies to drive MSD ANZ's continuous growth. She will also focus on optimizing business operations and governance within the region.
Lee joined MSD Korea in 2020 and has successfully led the External Affairs division over the past five years, where she oversaw the Communications, Policy, and Market Access teams.
Under her leadership, MSD Korea stressed that it has made significant progress in expanding patient access to key treatments, such as facilitating wider availability of Keytruda and ensuring the rapid inclusion of Vaxneuvance in the National Immunization Program (NIP).
Before joining MSD, Lee gained extensive experience in strategic communications and government affairs. She served as the Chief Marketing Officer (CMO) for Visa Korea and Mongolia and led the Communications and Policy team at Novartis Korea. Lee holds an MBA from Columbia University in the U.S. and a Master’s degree in Communications from Korea University.
Related articles
- Keytruda in triple-negative breast cancer faces accessibility challenges in Korea despite promising survival data
- [ESMO 2024] MSD remains cautious about when Keytruda’s SC formulation comes to market
- MSD’s Keytruda OKed as 1st line treatment of advanced endometrial cancer in Korea
- Keytruda gets expanded coverage for 11 indications at cancer disease panel
- MSD promotes Vaxneuvance ahead of showdown with Pfizer’s Prevnar20 in Korea’s vaccine market
- MSD Korea intensifies clinical collaborations to lead oncology innovation
